Extracorporeal Membrane Oxygenation (ECMO) Market by Type (Veno-Arterial ECMO, Veno-Venous ECMO, Arterio-Venous ECMO), By Application (Cardiac Surgery, Respiratory Failure, Neonatal Care, Cardiac Arrest), By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa); Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Extracorporeal Membrane Oxygenation Market was valued at USD 284.8 million in 2023 and will surpass USD 421.2 million by 2030; growing at a CAGR of 5.7% during 2024 - 2030.

The Extracorporeal Membrane Oxygenation (ECMO) market is primarily segmented based on the type of ECMO, with Veno-Arterial (VA-ECMO), Veno-Venous (VV-ECMO), and Arterio-Venous (AV-ECMO) being the main categories. VA-ECMO is considered the largest sub-segment, owing to its wide application in critical cardiac care, particularly for patients with severe cardiac and respiratory failure. It serves as a life-saving intervention for individuals who are experiencing cardiac arrest or undergoing major cardiac surgery, acting as both a heart and lung support system. VA-ECMO is increasingly preferred in intensive care units (ICUs) due to its ability to support both heart and lung function, making it vital during high-risk surgeries and in patients with combined heart and lung failure.

Veno-Arterial ECMO (VA-ECMO) is Largest Owing to Its Broad Application in Critical Cardiac Care

The demand for VA-ECMO is expected to continue rising as advancements in cardiovascular surgeries and heart failure treatments boost its application. With improvements in device portability and ease of use, VA-ECMO has found its place in both acute settings and long-term care for heart transplant candidates. The growing prevalence of cardiovascular diseases, along with improved survival rates in patients undergoing complex cardiac surgeries, ensures that VA-ECMO remains a dominant choice in the ECMO market.

Respiratory Failure is the Fastest Growing Application Segment

The ECMO market is also segmented by application, with major categories including cardiac surgery, respiratory failure, neonatal care, cardiac arrest, and others. Respiratory failure is the fastest-growing application, driven by increasing cases of chronic obstructive pulmonary disease (COPD), pneumonia, and COVID-19-related respiratory complications. ECMO has gained prominence in managing severe respiratory failure when conventional ventilator support is insufficient. This has been particularly evident in the wake of the COVID-19 pandemic, which saw a surge in the need for ECMO support due to respiratory failure in critically ill patients.

Respiratory failure's growing prevalence, especially in elderly populations and those with comorbidities, is anticipated to drive the rapid expansion of ECMO applications. As hospitals continue to enhance their ICU capabilities and invest in advanced life support technologies, ECMO for respiratory failure is becoming an increasingly accessible and effective solution. The market for ECMO devices dedicated to respiratory failure is expected to expand further with continuous improvements in device technology, safety features, and ease of integration into existing healthcare infrastructures.

Hospitals are Largest End-User Segment

The end-user segment of the ECMO market includes hospitals, specialty clinics, ambulatory surgical centers, and research institutes. Hospitals represent the largest sub-segment, driven by the critical care needs of patients requiring advanced life support. Intensive care units (ICUs) in hospitals, particularly those specializing in cardiac and respiratory care, are at the forefront of ECMO usage. The need for ECMO in hospitals is further amplified by the growing number of patients suffering from heart failure, respiratory diseases, and those undergoing high-risk surgeries, all of which require intensive monitoring and support.

Hospitals are increasingly adopting ECMO due to their ability to provide 24/7 care and a multi-disciplinary approach for patients in life-threatening conditions. The expanding hospital infrastructure, especially in emerging markets, is expected to further boost the demand for ECMO systems. Given that hospitals offer comprehensive care across various medical disciplines, they will continue to be the primary end-users of ECMO devices, cementing their position as the dominant segment in the market.

North America is the Largest Regional Market

In terms of regional analysis, North America holds the largest market share for ECMO, driven by advanced healthcare infrastructure, high healthcare expenditure, and an aging population. The United States, in particular, is the leading market for ECMO, with hospitals and specialty healthcare providers adopting the technology for critical care applications. North America's dominance is also attributed to the region's high prevalence of cardiovascular diseases, respiratory disorders, and the increasing number of heart surgeries. Additionally, government reimbursement policies for ECMO procedures and continuous investments in healthcare innovation further bolster the adoption of ECMO technologies in the region.

North America is expected to maintain its leadership position due to ongoing advancements in medical technology, increased awareness of ECMO's life-saving potential, and the growing number of ECMO-trained healthcare professionals. Furthermore, the presence of leading ECMO device manufacturers in the region ensures continuous innovation and availability of state-of-the-art ECMO solutions, supporting the region's growth.

Competitive Landscape and Leading Companies in the ECMO Market

The ECMO market is highly competitive, with several global and regional players vying for market share. Leading companies include Medtronic, LivaNova PLC, Terumo Corporation, Maquet Getinge Group, and Fresenius Medical Care, among others. These companies dominate the market through continuous innovation, strategic partnerships, and acquisitions. For instance, Medtronic and LivaNova are key players in the development of next-generation ECMO systems, focused on improving ease of use, portability, and patient outcomes.

The competitive landscape is marked by a strong emphasis on technological advancements, such as the development of portable ECMO devices and systems that offer enhanced monitoring features. Companies are also focusing on increasing awareness about ECMO’s life-saving potential, particularly in critical care scenarios. Additionally, the growing trend of partnerships between ECMO device manufacturers and hospitals or healthcare networks is expected to drive market expansion. Strategic mergers and acquisitions in the ECMO space are likely to lead to further consolidation, enabling companies to strengthen their product offerings and expand their global footprint.

Recent Developments:

• Medtronic launched a new ECMO system in 2024, designed to improve patient outcomes with advanced oxygenation and circulation control features.
• LivaNova PLC acquired a strategic partnership with a European hospital network to enhance ECMO adoption and training initiatives in 2023.
• Maquet Getinge Group received FDA approval for its next-generation ECMO machine, aimed at reducing complications in cardiac surgeries, in late 2023.
• Fresenius Medical Care announced a collaboration with a leading research institute to develop a more efficient ECMO device for pediatric patients in 2024.
• Terumo Corporation expanded its ECMO product line with the release of a new portable ECMO system designed for use in mobile care units in 2023.

List of Leading Companies:

• Medtronic
• LivaNova PLC
• Terumo Corporation
• Maquet Getinge Group
• Fresenius Medical Care
• Shimadzu Corporation
• Nipro Corporation
• Sorin Group
• Carmeda AB
• Xenios AG
• Medos Medizintechnik AG
• Eurosets
• Getinge AB
• Mölnlycke Health Care
• Baxter International Inc.

Report Scope: